Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7279518 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1LMNAL3MBTL1TRPA1 | |
| SCHEMBL27310163 | 0.79 | LMNA (0.52) | KDM4EALDH1A1LMNAL3MBTL1TRPA1 | |
| SCHEMBL11001287 | 0.77 | LMNA (0.40) | KDM4EALDH1A1LMNAL3MBTL1TRPA1 | |
| SCHEMBL11001286 | 0.77 | LMNA (0.40) | KDM4EALDH1A1LMNAL3MBTL1TRPA1 | |
| SCHEMBL1298318 | 0.77 | LMNA (0.50) | KDM4ELMNAL3MBTL1AOC3TSHR | |
| SCHEMBL27418272 | 0.74 | TRPA1 (0.57) | KDM4EALDH1A1LMNATRPA1AOC3 | |
| SCHEMBL28189063 | 0.74 | TRPA1 (0.38) | KDM4ELMNAL3MBTL1TRPA1HRH1 | |
| SCHEMBL11572796 | 0.74 | TRPA1 (0.41) | KDM4ELMNAL3MBTL1TRPA1HRH1 | |
| SCHEMBL27658747 | 0.74 | LMNA (0.42) | KDM4EALDH1A1LMNAL3MBTL1AOC3 | |
| SCHEMBL9656453 | 0.74 | LMNA (0.46) | KDM4ELMNAL3MBTL1MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | claimed |
| EP-1663962-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORP (US) | 2007-08-22 | — | — | EP | claimed |
| JP-2007503392-A | — | — | 2007-02-22 | — | — | JP | claimed |
| EP-1663962-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2006-06-07 | — | — | EP | claimed |
| CN-1784402-A | Imidazo and thiazolopyridines as JAK3 kinase inhibitors | ASTRAZENECA AB (SE) | 2006-06-07 | — | — | CN | claimed |
| US-20050054651-A1 | Compositions and methods for the treatment of disease associated with Trp-p8 expression | DENDREON CORPORATION (US) | 2005-03-10 | — | — | US | claimed |
| WO-2005020897-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2005-03-10 | — | — | WO | claimed |
| US-20020103381-A1 | Method for the synthesis of pyrazolines | CHEMRX ADVANCED TECHNOLOGIES, INC. | 2002-08-01 | — | — | US | claimed |
| WO-2001040193-A1 | METHOD FOR THE SYNTHESIS OF PYRAZOLINES | CHEMRX ADVANCED TECHNOLOGIES, INC. (US) | 2001-06-07 | — | — | WO | claimed |
| US-20150266810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | V-BAC HOLDING CORP. (CA) | 2015-09-24 | — | — | US | disclosed |
| US-9062205-B2 | Alkyl amine compounds for fluorescent labeling | BLOOD CELL STORAGE, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| EP-1781675-B1 | PHOSPHONATE FLUORESCENT DYES AND CONJUGATES | EPOCH BIOSCIENCES INC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-8389745-B2 | Phosphonate fluorescent dyes and conjugates | ELITECH HOLDING B.V. (NL) | 2013-03-05 | — | — | US | disclosed |
| WO-2001083434-A2 | P-(SULFONYL)-ARYL AND HETEROARYLS AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001064958-A2 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | EPOCH BIOSCIENECS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001029041-A1 | ALKYLAMINO SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001029042-A1 | HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
| US-4956363-A | 2-amino-4-morpholino-6-propyl-1,3,5-triazine | U C B S.A. (BE) | 1990-09-11 | — | — | US | disclosed |
| US-4956367-A | COGNITION ACTIVATORS, ALZHEIMER*S DISEASE | U C B S.A. (BE) | 1990-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | KDM4E 3888/4885ALDH1A1 4716/4885LMNA 2189/4885 |
| US-20020103381-A1 | Method for the synthesis of pyrazolines | CYP2F1, CYP2E1, CYP3A7 | KDM4E 3749/4885ALDH1A1 223/4885LMNA 2689/4885 |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | KDM4E 4239/4885ALDH1A1 4742/4885LMNA 1738/4885 |
| US-20150266810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | KDM4E 3849/4885ALDH1A1 4724/4885LMNA 2320/4885 |
| US-20050054651-A1 | Compositions and methods for the treatment of disease associated with Trp-p8 expression | TRPC4, TRPC3, TRPC1 | KDM4E 4239/4885ALDH1A1 4742/4885LMNA 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.